NEW YORK, March 23 (Reuters) - Catalent Inc said on Tuesday it had received the U.S. regulatory authorization it needs to produce Johnson & Johnson’s COVID-19 vaccine at its Bloomington, Indiana facility in the United States.
Reporting by Caroline Humer Editing by Chris Reese
我们的标准: 汤森路透“信任原则”